Pulsed Field Ablation as Initial Therapy for Persistent Atrial Fibrillation

Authors, Journal, Affiliations, Type, DOI

• Oussama M. Wazni, K.R. Julian Chun, Devi G. Nair, Ante Anic, Mattias Duytschaever, Jonathan Chrispin, et al. (AVANT GUARD Study Investigators)
• New England Journal of Medicine (NEJM 2026;394:2407-18)
• Multicenter international (Cleveland Clinic lead; Frankfurt, Jonesboro, Split, Bruges, Baltimore, et al.)
• Phase 3 randomized controlled trial (2:1 randomization; plus safety-assigned PFA group)
• DOI: 10.1056/NEJMoa2600929
• Funded by Boston Scientific (FARAPULSE manufacturer)

Overview

The AVANT GUARD trial is the first randomized controlled trial to evaluate pulsed field ablation (PFA) as first-line rhythm control therapy for previously untreated persistent atrial fibrillation. In this international multicenter trial, 310 patients were randomized 2:1 to PFA (pulmonary vein isolation + posterior wall ablation with the pentaspline FARAWAVE catheter) or antiarrhythmic drug therapy, with all patients receiving an insertable cardiac monitor for continuous rhythm monitoring. At 12 months, treatment success (composite of short-term procedural success and long-term freedom from atrial arrhythmia recurrence, repeat ablation, or AAD use) was significantly higher with PFA (56%) than with AADs (30%), for a hazard ratio for treatment failure of 0.46 (P<0.001). The primary safety endpoint was met (5.1% device/procedure-related SAEs vs 12% performance goal), but the trial was temporarily paused after 6 procedure-related strokes; no further strokes occurred after protocol modifications (mandatory TEE/CT within 24h, uninterrupted OAC ≥4 weeks, ACT ≥350s, exclusion of CHA₂DS₂-VASc ≥4). This trial establishes PFA as a superior first-line strategy for persistent AF and extends the first-line ablation paradigm from paroxysmal to persistent AF.

Keywords

Persistent atrial fibrillation, pulsed field ablation, antiarrhythmic drug therapy, first-line rhythm control, insertable cardiac monitor, atrial arrhythmia burden

Key Takeaways

Trial Design

• International, multicenter, prospective, randomized (2:1), controlled trial sponsored by Boston Scientific
• Patients with symptomatic persistent AF (continuous 7d–365d), no prior class I/III AAD use for >7 consecutive days
• Roll-in phase (30 patients) excluded from endpoint analyses
• 310 randomized: 207 PFA vs 103 AAD; additional 100 PFA-assigned patients for safety endpoint only
• All patients received an insertable cardiac monitor (LUX-Dx, Boston Scientific) with standardized settings
• Primary effectiveness endpoint: composite of short-term success (procedural success in PFA / no ablation during blanking in AAD) and long-term success (freedom from atrial arrhythmia ≥30s symptomatic or ≥1h asymptomatic, repeat ablation, AAD use, amiodarone use through 12 months)
• Primary safety endpoint: device- or procedure-related serious adverse events in combined PFA group (randomized + assigned)

Trial Pause and Protocol Modifications

• Trial paused October 18, 2024 after 6 neurologic events observed
• Enrollment resumed November 7, 2024 after protocol modifications:
  • Exclusion of CHA₂DS₂-VASc score ≥4
  • Mandatory transesophageal echocardiography or CT for LA thrombus within 24h pre-procedure
  • Uninterrupted anticoagulation for ≥4 weeks pre-procedure
  • Minimum activated clotting time of 350 seconds before ablation
• Safety event rates: 6% before pause, 3% after pause; no strokes/TIAs after pause

Procedural Characteristics

• Acute pulmonary vein isolation confirmed in all PFA patients
• Mean procedural time: 85±32 minutes; LA dwell time: 51±20 minutes (inclusive of 20-min waiting period)
• Mean 45±11 applications for PVI + 25±9 for posterior wall ablation
• Cavotricuspid isthmus ablation in 8.2% of patients

Antiarrhythmic Drug Therapy

• Mean 1.2±0.5 unique AADs at 1.6±0.9 unique doses during 90-day blanking period
• Flecainide most frequently prescribed (57.2%, median 200 mg/day); sotalol second (28.2%, median 240 mg/day)
• Amiodarone excluded as first-line (not guideline-directed for persistent AF)
• Cardioversion performed in 64.2% of AAD group patients

Primary Effectiveness Results

• Treatment success at 12 months: PFA 56% (95% CI 48–63) vs AAD 30% (95% CI 21–40)
• Between-group difference: 26 percentage points (95% CI 14–38)
• HR for composite treatment failure: 0.46 (95% CI 0.33–0.65; P<0.001)
• Treatment effect consistent across prespecified subgroups and sensitivity analyses

Arrhythmia Recurrence Patterns

• Symptomatic AT/AF ≥30s: 2% PFA vs 3% AAD
• Asymptomatic AT/AF ≥1h: 30% PFA vs 46% AAD — this was the dominant failure mode in both groups
• Amiodarone use: 1% PFA vs 3% AAD
• Nonprotocol ablation: <1% PFA vs 6% AAD

Atrial Arrhythmia Burden (Secondary Endpoint)

• Median burden at 12 months: 0% (IQR 0.0–0.4) PFA vs 0.2% (IQR 0.0–4.5) AAD
• Median difference: −0.2 percentage points (IQR −0.3 to 0.0)
• Mean between-group difference: −6.5 percentage points (95% CI −10.7 to −2.3)
• Burden >0.1%: 35% PFA vs 53% AAD

Quality of Life

• Mean AFEQT change from baseline: +23.3±1.5 PFA vs +19.8±2.3 AAD at 12 months
• EQ-5D, MMSE-2, and WAIS-IV changes reported (similar between groups)

Safety

• Primary safety endpoint (Kaplan-Meier): 5.1% (upper 97.5% CI 8.6%) vs 12% performance goal — met
• 13 SAEs in 257 combined PFA patients:
  • Stroke: 6 (2%) — 1 air embolization from deflectable sheath; all NIHSS <5; all improved/full recovery
  • Vascular access complication: 2 (1%)
  • Heart block: 1 (<1%)
  • Cardiovascular/pulmonary adverse event: 2 (1%)
  • Pulmonary edema: 3 (1%)
• No deaths, MI, TIA, systemic thromboembolism, tamponade, or pericarditis among primary safety events
• At 12 months: serious adverse events 25% PFA vs 21% AAD (as-treated population)
• Safety improved after protocol pause: 6% pre-pause → 3% post-pause

Population Characteristics

• Mean age 68.1±8.5 (PFA) / 67.4±8.7 (AAD) — older than prior first-line PAF ablation trials
• Mean LVEF 56.3±7.4%; LA diameter 4.3±0.6 cm
• Mean CHA₂DS₂-VASc 2.6±1.5; hypertension 65%; diabetes 23%; sleep apnea 24%
• 80% with first persistent AF diagnosis <1 year before enrollment

Limitations of the Document

• Single ablation technique (pentaspline FARAWAVE) and lesion set — results not generalizable to other PFA catheters, energy sources, or lesion sets
• 12-month follow-up only — longer-term durability and outcomes unknown
• ICM inserted at treatment initiation, so change in arrhythmia burden from baseline could not be assessed
• Some AAD-group patients underwent ablation after treatment failure (guideline-consistent), potentially underestimating ablation's effect on arrhythmia burden
• Primary safety endpoint was single-arm comparison against performance goal, not randomized vs AAD — inherent difficulty comparing procedural complications (short-term) vs pharmacotherapy adverse effects (latent)
• After the pause, only 29% of PFA-treated patients were enrolled — limited power to determine whether improved safety was patient-related or procedure-related
• Antiarrhythmic drug dosing and selection per local practice (not protocol-standardized)
• No MRI-based cerebral lesion substudy as performed in ADVENT

Key Concepts Mentioned

• concepts/Pulsed-Field-Ablation — first persistent AF RCT establishing first-line superiority; stroke safety signal and mitigation
• concepts/Catheter-Ablation-AF — extends first-line ablation evidence from paroxysmal to persistent AF
• entities/Atrial-Fibrillation — persistent AF rhythm control paradigm shift: PFA as initial strategy
• concepts/AF-CARE — rhythm control evidence strengthened for persistent AF
• concepts/Antiarrhythmic-Drugs — flecainide and sotalol as AAD comparators; amiodarone exclusion as first-line

Key Entities Mentioned

• entities/FARAPULSE — pentaspline PFA catheter (Boston Scientific) used in trial
• entities/Boston-Scientific — trial sponsor and PFA system manufacturer

Wiki Pages Updated

List every wiki page touched during this ingest.

• wiki/sources/PFA-LPeAF-AVANT-GUARD-NEJM-2026.md (created)
• wiki/sourceindex.md (updated)
• wiki/wikiindex.md (updated)
• wiki/concepts/Pulsed-Field-Ablation.md (updated — persistent AF efficacy + stroke safety signal)
• wiki/concepts/Catheter-Ablation-AF.md (updated — persistent AF first-line PFA data)
• wiki/log.md (appended)